IceCure Medical to Attend the 2025 Maxim Growth Summit
IceCure Medical (Nasdaq: ICCM) announced that management, including CEO Eyal Shamir, will attend the Maxim Growth Summit in New York City on October 22–23, 2025 for one-on-one investor meetings.
The company will present its corporate overview and recent regulatory and commercial progress, notably that its ProSense® cryoablation system received FDA marketing authorization for local treatment of early-stage, low-risk breast cancer in patients aged ≥70 and in women not suitable for surgery. ProSense is positioned as the first new device option for this defined indication in decades and may influence standards of care for the indicated population.
Investors were invited to schedule meetings via Maxim sales representatives or Michael Polyviou at mpolyviou@evcgroup.com.
IceCure Medical (Nasdaq: ICCM) ha annunciato che la dirigenza, incluso l'amministratore delegato Eyal Shamir, parteciperà al Maxim Growth Summit a New York City il 22–23 ottobre 2025 per incontri one-to-one con gli investitori.
L'azienda presenterà una panoramica aziendale e i progressi regolatori e commerciali recenti, in particolare il fatto che il sistema di crioablazione ProSense® ha ottenuto l'autorizzazione all'immissione in commercio FDA per il trattamento locale del cancro al seno in stadio precoce, a basso rischio, in pazienti di età ≥70 anni e in donne non idonee all'intervento chirurgico. ProSense è posizionato come la prima nuova opzione di dispositivo per questa indicazione definita da decenni e potrebbe influenzare gli standard di cura per la popolazione indicata.
Gli investitori sono stati invitati a fissare incontri tramite i rappresentanti di vendita di Maxim o tramite Michael Polyviou all'indirizzo mpolyviou@evcgroup.com.
IceCure Medical (Nasdaq: ICCM) anunció que la dirección, incluido el CEO Eyal Shamir, asistirá al Maxim Growth Summit en la ciudad de Nueva York los días 22–23 de octubre de 2025 para reuniones uno a uno con los inversores.
La empresa presentará una visión general corporativa y los progresos regulatorios y comerciales recientes, destacando que el sistema de crioablación ProSense® recibió la autorización de comercialización de la FDA para el tratamiento local del cáncer de mama en estadio temprano, de bajo riesgo, en pacientes de ≥70 años y en mujeres no aptas para cirugía. ProSense se posiciona como la primera nueva opción de dispositivo para esta indicación definida en décadas y podría influir en los estándares de atención para la población indicada.
Se invitó a los inversores a programar reuniones a través de los representantes de ventas de Maxim o de Michael Polyviou en mpolyviou@evcgroup.com.
IceCure Medical (나스닥: ICCM)은 이사회 및 CEO Eyal Shamir를 포함한 경영진이 2025년 10월 22~23일 뉴욕시에서 열리는 Maxim Growth Summit에 참석하여 투자자와의 1:1 미팅을 갖는다고 발표했습니다.
회사 업데이트 개요와 최근 규제 및 상업적 진전을 발표할 예정이며, 특히 ProSense® 냉동소작 시스템이 70세 이상 환자 및 수술에 적합하지 않은 여성의 초기 저위험 유방암에 대한 지역 치료를 위한 FDA 시판 허가를 받았다는 점을 강조합니다. ProSense는 수십 년 만에 이 정의된 적응증에 대한 최초의 새로운 기기 옵션으로 자리매김하며, 지적된 인구의 표준 치료에 영향을 미칠 수 있습니다.
투자자들은 Maxim의 영업 담당자나 Michael Polyviou(mpolyviou@evcgroup.com)에게 회의 예약을 권유받았습니다.
IceCure Medical (Nasdaq : ICCM) a annoncé que la direction, y compris le PDG Eyal Shamir, assistera au Maxim Growth Summit à New York les 22 et 23 octobre 2025 pour des entretiens investisseurs en tête‑à‑tête.
L'entreprise présentera un aperçu de sa gouvernance et les progrès réglementaires et commerciaux récents, notamment que le système de cryoablation ProSense® a reçu l'autorisation de mise sur le marché par la FDA pour le traitement local du cancer du sein précoce à faible risque chez les patientes âgées de 70 ans et plus et chez les femmes non éligibles à une chirurgie. ProSense est positionné comme la première nouvelle option d'appareil pour cette indication définie depuis des décennies et pourrait influencer les standards de soins pour la population indiquée.
Les investisseurs étaient invités à programmer des réunions via les représentants commerciaux de Maxim ou via Michael Polyviou à mpolyviou@evcgroup.com.
IceCure Medical (Nasdaq: ICCM) hat bekannt gegeben, dass das Management, einschließlich CEO Eyal Shamir, am Maxim Growth Summit in New York City am 22.–23. Oktober 2025 für One-on-One-Investorengespräche teilnehmen wird.
Das Unternehmen wird einen Überblick über das Unternehmen und die jüngsten regulatorischen sowie kommerziellen Fortschritte präsentieren, insbesondere dass das ProSense®-Kryoablation-System die FDA-Vertriebszulassung für die lokale Behandlung von frühem, risikoarmem Brustkrebs bei Patientinnen ≥70 Jahren und bei Frauen, die sich keiner Operation unterziehen können, erhalten hat. ProSense positioniert sich als erste neue Gerätemöglichkeit für diese definierte Indikation seit Jahrzehnten und könnte die Behandlungsstandards für die angegebene Population beeinflussen.
Investoren wurden eingeladen, Meetings über Maxim-Vertriebsmitarbeiter oder über Michael Polyviou unter mpolyviou@evcgroup.com zu vereinbaren.
IceCure Medical (ناسداك: ICCM) أعلنت أن الإدارة، بمن فيهم الرئيس التنفيذي إيال شامير، ستشارك في قمة Maxim Growth Summit في مدينة نيويورك في 22–23 أكتوبر 2025 لعقد اجتماعات فردية مع المستثمرين.
ستقدم الشركة عرضاً عاماً عن الشركة والتقدمات التنظيمية والتجارية الأخيرة، ولا سيما أن نظام التجميد والتبريد ProSense® تلقّى تصريح التسويق من FDA لعلاج موضعي للسرطان الثديي في مراحله المبكرة وبخطورة منخفضة لدى المرضى الذين تبلغ أعمارهم ≥70 عامًا وبالنسبة للنساء غير القادرات على الخضوع للجراحة. يُنظر إلى ProSense كأول خيار جهاز جديد لهذه المؤشّرة المحدّدة منذ عقود وقد يؤثر على معايير الرعاية لهذه الشريحة من السكان.
دُعي المستثمرون إلى جدولة الاجتماعات عبر ممثلي مبيعات Maxim أو عبر مايكل بولفيولو على mpolyviou@evcgroup.com.
IceCure Medical（纳斯达克：ICCM） 宣布管理层，包括首席执行官 Eyal Shamir，将于 2025 年 10 月 22–23 日 参加在纽约市举行的 Maxim Growth Summit，进行与投资者的一对一会面。
公司将介绍其企业概览以及近期在监管和商业方面的进展，特别是其 ProSense® 低温消融系统 已获得 FDA 的 上市许可，用于对高龄≥70 岁且不适合手术的早期、低风险乳腺癌的局部治疗。ProSense 被定位为数十年来在该明确适应症下的首个新设备选项，可能影响该人群的治疗标准。
投资者被邀请通过 Maxim 的销售代表或通过 Michael Polyviou（mpolyviou@evcgroup.com）安排会谈。
- None.
- None.
IceCure recently achieved a significant milestone—ProSense® Cryoablation system became the first and only medical device to be granted FDA marketing authorization for the local treatment of breast cancer
IceCure's ProSense® cryoablation system recently received the
Investors should reach out to their Maxim sales representatives, or Michael Polyviou at mpolyviou@evcgroup.com to schedule meetings with IceCure Medical's management team.
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses the participation of members of management at the Maxim Growth Summit. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC on March 27, 2025, and other documents filed with or furnished to the SEC which are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. Information available on or through the websites mentioned in this press release does not form part of this press release.
IR Contact:
Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Logo - https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/icecure-medical-to-attend-the-2025-maxim-growth-summit-302579488.html
SOURCE IceCure Medical
FAQ
When will IceCure Medical (ICCM) management attend the Maxim Growth Summit?
Who from IceCure will be available for investor meetings at the October 2025 summit?
What regulatory milestone did IceCure report before the October 2025 summit?
How can investors schedule a meeting with IceCure (ICCM) at the Maxim Growth Summit?
What will IceCure discuss with investors at the October 2025 Maxim Growth Summit?
